Faron Pharmaceuticals
1.548 EUR +2.25%Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The company currently has a pipeline based on the endothelial receptors involved in regulation of immune response, in oncology and organ damage. Our pipeline consists of two drug candidates and development programmes Clevegen (FP-1305) and Traumakine (FP-1201-lyo). Clevegen aims to tackle several cancer types by activating immunity; Traumakine organ trauma and vascular damage by stopping vascular leakage. Both programmes have advanced to first-in-human clinical trials following promising pre-clinical data. Faron is based in Turku, Finland.
Read moreLatest research
Extensive report
Analyst
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Citibank Europe PLC | 34.4 % | 34.4 % |
Skandinaviska Enskilda Banken AB | 7.9 % | 7.9 % |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.7 | 9.8 |
growth-% | 117,402.0 % | 109.5 % | ||||||
EBITDA | -16.4 | -20.8 | -27.4 | -28.2 | -29.5 | -31.0 | -27.7 | -22.3 |
EBIT (adj.) | -16.7 | -21.1 | -27.4 | -28.6 | -29.9 | -31.2 | -27.9 | -22.4 |
EBIT | -16.7 | -21.1 | -27.4 | -28.6 | -29.9 | -31.2 | -27.9 | -22.4 |
Profit before taxes | -16.9 | -21.2 | -28.7 | -30.9 | -32.5 | -33.8 | -30.8 | -25.6 |
Net income | -16.9 | -21.2 | -28.6 | -30.9 | -32.5 | -33.8 | -30.8 | -25.6 |
EPS (adj.) | -0.36 | -0.40 | -0.48 | -0.45 | -0.31 | -0.32 | -0.29 | -0.24 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -409,275.0 % | -520,050.0 % | -685,675.0 % | -705,550.0 % | -738,215.0 % | -775,945.0 % | -589.8 % | -226.1 % |
EBIT-% (adj.) | -416,350.0 % | -527,700.0 % | -685,650.0 % | -714,200.0 % | -748,215.0 % | -780,662.5 % | -593.2 % | -227.5 % |
EBIT-% | -416,350.0 % | -527,700.0 % | -685,650.0 % | -714,200.0 % | -748,215.0 % | -780,662.5 % | -593.2 % | -227.5 % |
ROE | 14,063.1 % | -3,920.3 % | 670.4 % | 232.3 % | 266.8 % | 129.4 % | 52.6 % | 29.5 % |
ROI | -676.3 % | -588.9 % | -707.3 % | 7,250.8 % | 4,536.4 % | -3,566.0 % | -3,696.2 % | -3,399.4 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 2.91 | 3.24 | 3.41 | 3.77 | 1.55 | 1.55 | 1.55 | 1.55 |
Shares | 46.9 | 53.2 | 59.8 | 68.8 | 106.4 | 106.4 | 106.4 | 106.4 |
Market cap | 136.5 | 172.5 | 203.6 | 259.3 | 164.6 | 164.6 | 164.6 | 164.6 |
Enterprise value | 135.1 | 169.0 | 209.6 | 265.3 | 167.8 | 201.5 | 232.2 | 257.6 |
EV/S | 33,775.4 | 42,241.4 | 52,395.5 | 66,337.2 | 41,952.4 | 50,378.5 | 49.4 | 26.2 |
EV/EBITDA | - | - | - | - | - | - | - | - |
EV/EBIT (adj.) | - | - | - | - | - | - | - | - |
EV/EBIT | - | - | - | - | - | - | - | - |
P/E (adj.) | - | - | - | - | - | - | - | - |
P/E | - | - | - | - | - | - | - | - |
P/B | - | 58.8 | - | - | - | - | - | - |
P/S | 34,117.3 | 43,117.9 | 50,904.8 | 64,831.5 | 41,158.2 | 41,158.2 | 35.0 | 16.7 |
Dividend yield | ||||||||
Equity ratio | -22.1 % | 22.3 % | -101.8 % | -148.4 % | -88.4 % | -417.9 % | -723.8 % | -982.5 % |
Gearing ratio | 73.9 % | -119.5 % | -52.0 % | -39.7 % | -34.4 % | -85.6 % | -91.5 % | -93.6 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | ||||||
EBITDA | -12.6 | -15.6 | -28.2 | -13.9 | -15.7 | ||||
EBIT | -12.8 | -15.8 | -28.6 | -14.1 | -15.9 | ||||
Profit before taxes | -13.7 | -17.2 | -30.9 | -15.3 | -17.2 | ||||
Net income | -13.7 | -17.2 | -30.9 | -15.3 | -17.2 |
Faron Pharmaceuticals Oy: Appointment of Chief Financial Officer
Faron Pharmaceuticals Oy: Approval of Warrant Terms and Conditions
Join Inderes community
Don't miss out - create an account and get all the possible benefits